Evidence map›Paper›PMID 34794469›Full record

ArticleMolecular brain2021

Conditional deletion of ROCK2 induces anxiety-like behaviors and alters dendritic spine density and morphology on CA1 pyramidal neurons.

Audrey J Weber, Ashley B Adamson, Kelsey M Greathouse, Julia P Andrade, Cameron D Freeman, Jung Vin Seo, Rosaria J Rae, Courtney K Walker, Jeremy H Herskowitz

Open access · goldAbstract read
In one paragraph

Article in Molecular brain, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.1field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Article
  3. Rock inhibitors in Alzheimer's disease.Frontiers in aging · 2025
    Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Audrey J WeberCenter for Neurodegeneration and Experimental Therapeutics, Department of Neurology, University of Alabama at Birmingham, 1825 University Blvd, Birmingham, AL, 35294, USA.
Ashley B AdamsonCenter for Neurodegeneration and Experimental Therapeutics, Department of Neurology, University of Alabama at Birmingham, 1825 University Blvd, Birmingham, AL, 35294, USA.
Kelsey M GreathouseCenter for Neurodegeneration and Experimental Therapeutics, Department of Neurology, University of Alabama at Birmingham, 1825 University Blvd, Birmingham, AL, 35294, USA.
Julia P AndradeCenter for Neurodegeneration and Experimental Therapeutics, Department of Neurology, University of Alabama at Birmingham, 1825 University Blvd, Birmingham, AL, 35294, USA.
Cameron D FreemanCenter for Neurodegeneration and Experimental Therapeutics, Department of Neurology, University of Alabama at Birmingham, 1825 University Blvd, Birmingham, AL, 35294, USA.
Jung Vin SeoCenter for Neurodegeneration and Experimental Therapeutics, Department of Neurology, University of Alabama at Birmingham, 1825 University Blvd, Birmingham, AL, 35294, USA.
Rosaria J RaeCenter for Neurodegeneration and Experimental Therapeutics, Department of Neurology, University of Alabama at Birmingham, 1825 University Blvd, Birmingham, AL, 35294, USA.
Courtney K WalkerCenter for Neurodegeneration and Experimental Therapeutics, Department of Neurology, University of Alabama at Birmingham, 1825 University Blvd, Birmingham, AL, 35294, USA.
Jeremy H HerskowitzCenter for Neurodegeneration and Experimental Therapeutics, Department of Neurology, University of Alabama at Birmingham, 1825 University Blvd, Birmingham, AL, 35294, USA. jhersko@uab.edu.ORCID 0000-0002-7227-1470
University of Alabama at Birmingham · US

Funding

Identifying therapeutic targets that confer synaptic resilience to Alzheimer's diseaseR01AG061800 · NIA · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI Christopher A. Gaiteri, Jeremy H. Herskowitz · 2018 to 2026
$6.9M
UAB Research Training Program in Neurobiology of Cognition and Cognitive DisordersT32NS061788 · NINDS · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI Farah Dominique Lubin · 2008 to 2026
$4.5M
Identifying the molecular systems, networks, and key molecules that underlie cognitive resilienceR01AG057911 · NIA · UPSTATE MEDICAL UNIVERSITY · PI GAITERI, CHRISTOPHER A. · 2017 to 2021
$3.8M
Targeting Rho Kinases for Alzheimer's disease TherapeuticsR01AG054719 · NIA · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI HERSKOWITZ, JEREMY H. · 2017 to 2021
$1.9M
UAB Training Program In NeuroscienceT32NS095775 · NINDS · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI Erik D Roberson · 2017 to 2026
$1.6M
Pathologic tau and dendritic spine loss in Alzheimer's diseaseF31AG067635 · NIA · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI WALKER, COURTNEY KAITLIN · 2020 to 2021
$75k
NIA NIH HHS F31 AG067635NIA NIH HHS R01 AG054719NIA NIH HHS R01 AG057911NIA NIH HHS R01 AG061800NINDS NIH HHS T32 NS061788NINDS NIH HHS T32 NS095775
6 · The paper itself

Abstract

Rho-associated kinase isoform 2 (ROCK2) is an attractive drug target for several neurologic disorders. A critical barrier to ROCK2-based research and therapeutics is the lack of a mouse model that enables investigation of ROCK2 with spatial and temporal control of gene expression. To overcome this, we generated ROCK2

Indexed as

Dendritic SpinesPyramidal CellsAnimalsAnxietyCA1 Region, HippocampalDendritesHippocampusMicerho-Associated Kinasesrho-Associated KinasesRock2 protein, mouseAmygdalaDendritic spineHippocampusPrefrontal cortexRho kinaseROCK2

Identifiers

PMID34794469
PMCPMC8600782
OpenAlexW3211704718

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.